DJIA 17,712.66 34.43 0.19%
NASDAQ 4,891.22 27.86 0.57%
S&P 500 2,061.02 4.87 0.24%
market minute promo

PHARMACYCLICS, INC. (NASDAQ: PCYC)

256.62 0.25 (0.10%)

REAL-TIME: Last trade at

Extended Hours: $256.95 $0.39 (0.15%)
Quote as of (NASDAQ)



company name or ticker

Recent Quotes

PCYC $256.62 0.10%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $256.90
Previous Close $256.37
Daily Range $256.14 - $257.72
52-Week Range $82.51 - $258.95
Market Cap $19.5B
P/E Ratio 233.06
Dividend (Yield) $0.00 (0.0%)
Volume 704,361
Average Daily Volume 2,299,572
Current FY EPS $0.26

Sector

Healthcare

Industry

Drug Makers

PHARMACYCLICS, INC. (PCYC) Description

A pharmaceutical company focused on the development of products that improve existing therapeutic approaches to cancer and other diseases. Website: http://www.pharmacyclics.com/

News & Commentary

Better Dividend Stock: AbbVie or Gilead Sciences, Inc.?

AbbVie and Gilead are two closely followed dividend stocks in the healthcare sector. Which one offers investors the better long-term prospects moving forward?

Pharmacyclics, BioMarin, And Incyte: A Quick Screen

New ETF From BlackRock And Edelman

New ETF From BlackRock And Edelman

3 Stocks Reiterated As A Hold: PCYC, LNKD, PM

Biotech Stocks Are Selling Off Just Like 2014 -- and That Might Be a Good Thing

Confessions of a Value Investor Stuck in a High-Growth Industry

It's OK to buy premium-priced biotechs.

The Zacks Analyst Blog Highlights: Amgen, Regeneron, Nektar, ACADIA and Pharmacyclics - Press Releas

The Zacks Analyst Blog Highlights: Amgen, Regeneron, Nektar, ACADIA and Pharmacyclics - Press Releases

Biotech Stock Roundup: Amgen & Regeneron Shine at ACC, Nektar Drug Disappoints - Analyst Blog

Pharmacyclics' Imbruvica Encourages in a Phase III Study - Analyst Blog

See More PCYC News...

PCYC's Top Competitors

PCYC $256.62 (0.10%)
Current stock: PCYC
AMGN $162.59 (1.27%)
Current stock: AMGN
GILD $101.00 (-0.07%)
Current stock: GILD
BIIB $429.87 (0.22%)
Current stock: BIIB